Rho激酶信号通路在两肾一夹肾性高血压大鼠心肌肥大中的作用及Fasudil干预

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (6): 657-662.

Rho激酶信号通路在两肾一夹肾性高血压大鼠心肌肥大中的作用及Fasudil干预

汪祥海¹, 伍卫², 杨玉雯¹, 夏朝红¹

¹皖南医学院弋矶山医院心内科, 芜湖 241001, 安徽;
²中山大学附属第二医院心内科, 广州 510120, 广东

收稿日期:2008-05-22 修回日期:2008-06-22 发布日期:2020-10-14
作者简介:汪祥海,男,博士,主治医师,研究方向:冠心病、高血压的基础与临床。Tel:15605539788 E-mail:wangxianghai@163.com
基金资助:
广东省科委基金项目(2004Z3-E0331)

Role of Rho-kinase signal pathway on myocardium hypertrophy of 2K1C renal hypertension rats and effects of Fasudil

WANG Xiang-hai¹, WU Wei², YANG Yu-wen¹, XIA Chao-hong¹

¹Department of Cardiology, Affiliated Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China;
²Department of Cardiology, Second Affiliated Hospital of SunYat-sen University, Guangzhou 510120, Guangdong, China

Received:2008-05-22 Revised:2008-06-22 Published:2020-10-14

摘要/Abstract

摘要： 目的: 了解Rho激酶介导的信号转导通路在两肾一夹(two-kidneys-one-clip,2K1C)肾性高血压大鼠心肌肥大发病机制中的作用以及特异性Rho激酶抑制剂Fasudil干预效应。方法: 制备两肾一夹肾性高血压大鼠模型,实验设假手术组、模型组、实验组(Fasudi l10 mg·kg^-1·d^-1腹腔注射)。电子天平称量左心室质量并计算左心室质量与体质量比值;光学显微镜观察心肌组织形态学变化;Western blotting检测肌球蛋白结合亚基磷酸化(phosphorylation of myosin-binding submet,MBS-P)表达作为Rho激酶功能活化标志;RT-PCR检测Rho激酶mRNA表达。结果: 术后12周,模型组大鼠出现较显著的心肌肥大(P<0.01),心肌组织Rho激酶活性及mRNA表达显著增加(P<0.01)且Rho激酶活性及mRNA表达与心肌肥大程度间呈显著正相关(P<0.05)。Rho激酶特异性抑制剂Fasudil在抑制大鼠心肌组织Rho激酶活化和mRNA表达的同时可有效抑制心肌肥大的发展(P<0.01)。结论: Rho激酶介导的信号转导通路在2K1C肾性高血压大鼠心肌肥大发病机制中可能具有重要作用,Rho激酶特异性抑制剂Fasudil可有效抑制心肌肥大的发展。

关键词: 高血压, 两肾一夹, Rho激酶, 大鼠

Abstract: AIM: To investigate the role of Rhokinase mediated signal pathway on myocardium hypertrophy of two-kidneys-one-clip (2K1C) renal hypertension rats and effects of fasudil.METHODS: 2K1C renal hypertensive model was established in Sprague-Dawley rats by chronic partial occlusion of left renal artery.The rats were randomly divided into 3 groups: Sham Group, Model Group, Experimental Group(Fasudil 10mg·kg^-1·d^-1, intraperitoneal injection).Left ventricular mass and left ventricular mass to body mass ratio were measured with electronic balance.Myocardial histomorphology was observed by light microscope. The extent of phosphorylation of myosin-binding submet (MBS-P) of myosin phosphatase was quantified by western blotting analysis, and it was used to evaluate the activity of Rho-kinase.The expression of Rho-kinase mRNA was examined by RT-PCR analysis.RESULTS: At 12th week after renovascular constriction, there was noticeable myocardial hypertrophy in Model Group(P<0.01).The Rho-kinase activity and Rho-kinase mRNA expression were significantly increased in Model Group(P<0.01).There was a positive correlation between Rho-kinase activity and myocardial hypertrophy (P<0.05), and there was a positive correlation between Rho-kinase mRNA expression and myocardial hypertrophy in Model Group(P<0.05).Fasudil-a Rho-kinase specific inhibitor, effectively inhibited myocardial hypertrophy and prevented changes of Rho-kinase activity and mRNA expression in renal hypertension rats (P<0.01).CONCLUSION: The Rho-kinase mediated signal pathway may play an important role in the development of myocardial hypertrophy in 2K1C renal hypertension rats.

Key words: hypertension, two-kidneys-one-clip, Rho-kinase, rat

中图分类号:

R541.

汪祥海, 伍卫, 杨玉雯, 夏朝红. Rho激酶信号通路在两肾一夹肾性高血压大鼠心肌肥大中的作用及Fasudil干预[J]. 中国临床药理学与治疗学, 2008, 13(6): 657-662.

WANG Xiang-hai, WU Wei, YANG Yu-wen, XIA Chao-hong. Role of Rho-kinase signal pathway on myocardium hypertrophy of 2K1C renal hypertension rats and effects of Fasudil[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(6): 657-662.

参考文献

[1] Poster GR, Brown JH. G protein-coupled receptors and signaling pathways regulating growth responses [J]. FASEB J, 1996, 10(7): 741-749.
[2] Riento K, Ridley AJ. Rocks:multifunctional kinases in cell be haviour[J]. Nat Rev Mol Cell Biol, 2003, 4(6): 446-456.
[3] Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decode of hypertrophic signaling hits[J]. Cire Res, 2006, 98(6): 730-742.
[4] Wettschureck N, Offermanns S. Rho/ Rho-kinase mediated signaling in phy siology and pathophysiology[J]. J Mol Med, 2002, 80(10): 629-638.
[5] Morikawa-Futamatsu K, Adachi S, Maejima Y, et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1[J]. Life Sci, 2006, 79(14): 1380-1390.
[6] Zeidan A, Javadov S, KarmazynM. Essential role of Rho ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes[J]. Cardiovasc Res, 2006, 72(1): 101-111.
[7] Wang YX, da Cunha V, Martin-McNulty B, et al. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice[J]. Eur J Pharmacol, 2005, 512(2/3): 215-222.
[8] Yanazume T, Hasegawa K, Wada H, et al. Rho ROCK pathway contributes to the activation of extracellular signal-regulated kinase GATA-4 during myocardial cellhypertrophy[J]. J Biol Chem, 2002, 277 (10): 8618-8625.
[9] Higashi M, Shimokawa H, Hattori T. Long-term inhibition of Rho-kinase suppresses angiotensin Ⅱ induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P) H oxidase system[J]. Circ Res, 2003, 93(8): 767-775.
[10] Ishimaru K, Ueno H, Kagitani S, et al. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte macrophage infiltration in the heart of DOCA salt hypertensive rats[J]. J Cardiovasc Pharmacol, 2007, 50 (2): 187-194.

[1]	许秀荷, 何晓丽, 周佳顺, 潘丽珠, 周卓君, 李佳悦, 王彩霞, 袁伟, 朱桂琦. 蜂蜜对大鼠血尿酸水平及肾损伤研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 743-750.
[2]	汪东辉, 蒋素文, 胡爱荣, 朱波, 何哲耘, 张露侃, 王家岚, 范莹, 林恳. 桑葚改善大鼠非酒精性脂肪性肝病的氧化应激损伤[J]. 中国临床药理学与治疗学, 2023, 28(6): 609-616.
[3]	李红琴, 曹利民, 金满意, 王建龙, 柴晓萍, 田苗苗. 牵正散不同剂型改善大鼠面神经损伤作用研究[J]. 中国临床药理学与治疗学, 2023, 28(6): 617-623.
[4]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[5]	衡冰冰, 杨丹峰, 戴舒阳, 上官王宁. 丙泊酚对皮下注射氯喹所致瘙痒大鼠脊髓TRPV1和CB1受体的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1101-1108.
[6]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[7]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[8]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[9]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[10]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[11]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[12]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[13]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.
[14]	张静, 高丹阳, 于康, 林晓婉, 曹颖, 刘晓, 缪慧慧, 李天佐. 不同吸入麻醉药对新生期大鼠神经胶质细胞活化的影响[J]. 中国临床药理学与治疗学, 2022, 27(12): 1391-1399.
[15]	张远金, 黄盛博, 刘洁, 王昕. 药物代谢创新模型：基因编辑大鼠和小肠3D类器官[J]. 中国临床药理学与治疗学, 2021, 26(8): 914-922.